Discovery of Novel Focal Adhesion Kinase Inhibitors Using a Hybrid Protocol of Virtual Screening Approach Based on Multicomplex-Based Pharmacophore and Molecular Docking
Focal adhesion kinase (FAK) is a tyrosine kinase that functions as a key orchestrator of signals leading to invasion and metastasis. In the current study, the multicomplex-based pharmacophore (MCBP)-guided method has been suggested to generate a comprehensive pharmacophore of FAK kinase based on seven crystal structures of FAK-inhibitor complexes. In this investigation, a hybrid protocol of virtual screening methods, comprising of pharmacophore model-based virtual screening (PB-VS) and docking-based virtual screening (DB-VS), is used for retrieving new FAK inhibitors from commercially available chemical databases. This hybrid virtual screening approach was then applied to screen several chemical databases, including the Specs (202,408 compounds) database. Thirty-five compounds were selected from the final hits and should be shifted to experimental studies. These results may provide important information for further research of novel FAK inhibitors.
References
[1]
Kanner, S.B.; Reynolds, A.B.; Vines, R.R.; Parsons, J.T. Monoclonal antibodies to individual tyrosine-phosphorylated protein substrates of oncogene-encoded tyrosine kinases. Proc. Natl. Acad. Sci. USA 1990, 87, 3328–3332.
[2]
Matkowskyj, K.A.; Keller, K.; Glover, S.; Kornberg, L.; Tran-Son-Tay, R.; Benya, R.V. Expression of GRP and its receptor in well-differentiated colon cancer cell score relates with the presence of focal adhesion kinase phosphorylated at tyrosines 397 and 407. J. Histochem. Cytochem 2003, 51, 1041–1048.
Schlaepfer, D.D.; Hunter, T. Signal transduction from the extracellular matrix: Role for the focal adhesion protein-tyrosine kinase FAK. Cell Struct. Funct 1996, 21, 445–450.
Gabarra-Niecko, V.; Schaller, M.D.; Unty, J.M. FAK regulates biological processes important for the pathogenesis of cancer. Cancer Metastasis Rev 2003, 22, 359–374.
[7]
McLean, G.W.; Carragher, N.O.; Avizienyte, E.; Evans, J.; Brunton, V.G.; Frame, M.C. The role of focal adhesion kinase in cancer, new therapeutic opportunity. Nat. Rev. Cancer 2005, 5, 505–515.
[8]
Sood, A.K.; Coffin, J.E.; Schneider, G.B.; DeYoung, B.R.; Gruman, L.M.; Gershenson, D.M.; Schaller, M.D.; Hendrix, M.J.C. Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion. Am. J. Pathol 2004, 165, 1087–1095.
[9]
Cance, W.G.; Harris, J.E.; Iacocca, M.V.; Roche, E.; Yang, X.H.; Chang, J.L.; Simkins, S.; Xu, L.H. Immunohistochemical analyses of focal adhesion kinase expression in benign and malignant human breast and colon tissues: Correlation with preinvasive and invasive phenotypes. Clin. Cancer Res 2000, 6, 2417–2423.
Jones, G.; Machado, J.; Tolnay, M.; Merlo, A. PTEN-independent induction of caspase-mediated cell death and reduced invasion by the focal adhesion targeting domain (FAT) in human astrocytic brain tumors which highly express focal adhesion kinase (FAK). Cancer Res 2001, 61, 5688–5691.
[12]
Golubovskaya, V.M.; Cance, W.G. Focal Adhesion Kinase and p53 Signaling in Cancer Cells. Int. Rev. Cytol 2007, 263, 103–153.
[13]
Hao, H.; Naomoto, Y.; Bao, X.; Watanabe, N.; Sakurama, K.; Noma, K.; Motoki, T.; Tomono, Y.; Fukazawa, T.; Shirakawa, Y.; et al. Focal adhesion kinase as potential target for cancer therapy. Onco. Rep 2009, 22, 973–979.
[14]
Slack-Davis, J.K.; Martin, K.H.; Tilghman, R.W.; Iwanicki, M.; Ung, E.J.; Autry, C.; Luzzio, M.J.; Cooper, B.; Kath, J.C.; Roberts, W.G.; et al. Cellular characterization of a novel focal adhesion kinase inhibitor. J. Biol. Chem 2007, 282, 14845–14852.
Marti-Renom, M.A.; Stuart, A.C.; Fiser, A.; Sanchez, R.; Melo, F.; Sali, A. Comparative protein structure modeling of genes and genomes. Annu. Rev. Biophys. Biomol. Struct 2000, 29, 291–325.
[19]
Lu, X.Y.; Chen, Y.D.; You, Q.D. 3D-QSAR studies of arylcarboxamides with inhibitory activity on InhA using pharmacophore-based alignment. Chem. Biol. Drug Des 2010, 75, 195–203.
[20]
Chaudhaery, S.S.; Roy, K.K.; Saxena, A.K. Consensus Superiority of the Pharmacophore-Based Alignment, Over Maximum Common Substructure (MCS): 3D-QSAR Studies on Carbamates as Acetylcholinesterase Inhibitors. J. Chem. Inf. Model 2009, 49, 1590–1601.
[21]
He, G.; Qiu, M.H.; Li, R.; Ouyang, L.; Wu, F.B.; Song, X.R.; Cheng, L.; Xiang, M.L.; Yu, L.T. Multicomplex-based pharmacophore-guided 3D-QSAR studies of N-substituted 2′-(amino-aryl-) benzothiazoles as Aurora-A inhibitors. Chem. Biol. Drug Des 2012, 79, 960–971.
[22]
Ouyang, L.; He, G.; Huang, W.; Song, X.R.; Wu, F.B.; Xiang, M.L. Combined Structure-Based Pharmacophore and 3D-QSAR Studies on Phenylalanine Series Compounds as TPH1 Inhibitors. Int. J. Mol. Sci 2012, 13, 5348–5363.
[23]
Berman, H.M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T.N.; Weissig, H.; Shindyalov, I.N.; Bourne, P.E. The protein data bank. Nucl. Acids Res 2000, 28, 235–242.
[24]
Courcy, B.; Piquemal, J.P.; Garbay, C.; Gresh, N. Polarizable Water Molecules in Ligand-Macromolecule Recognition. Impact on the Relative Affinities of Competing Pyrrolopyrimidine Inhibitors for FAK Kinase. J. Am. Chem. Soc 2010, 132, 3312–3320.
[25]
Discovery Studio, version 3.5; Accelrys Inc: San Diego, CA, USA, 2012.
[26]
Thangapandian, S.; John, S.; Sakkiah, S.; Lee, K.W. Potential virtual lead identification in the discovery of renin inhibitors: application of ligand and structure-based pharmacophore modeling approaches. Eur. J. Med. Chem 2011, 46, 2469–2476.
[27]
Irwin, J.J.; Sterling, T.; Mysinger, M.M.; Bolstad, E.S.; Coleman, R.G. ZINC: A Free Tool to Discover Chemistry for Biology. J. Chem. Inf. Model 2012, 52, 1757–1768.
